

## Wisconsin State Laboratory of Hygiene

UNIVERSITY OF WISCONSIN-MADISON







Dave Warshauer, PhD, D(ABMM)

Deputy Director, Communicable

Diseases

Wisconsin State Laboratory of Hygiene



- A. We have a GeneXpert ® in our lab and use the MTB/RIF assay
- B. We have a GeneXpert ® in our lab but do not use the MTB/RIF assay

- C. We don't have a GeneXpert ®
- D. MTB WHAT????????



## **Removing Patients from AII**

- Traditionally used 3 sputum smears collected early morning
  - Took a long time: average 5-7 days in isolation
  - Not sensitive 50-80%
  - Not specific 70-90% (depending on NTM and TB prevalence)
- Current guideline
  - 3 sputums collected 8-24 hr apart, with at least one being an early morning specimen



#### **Problems with Isolation**

- Average 5-7 days in isolation for TB
- Limited number of isolation rooms
- Patients seen less by HCWs
- 8 fold increase in adverse effects
- Have a negative perspective of their care
- Delays in getting procedures performed
- Most patients admitted into isolation do not have TB







GeneXpert ® System
Cepheid, Sunnyvale, CA
RT-PCR, < 2 hours



## GeneXpert® MTB/RIF Assay

- Automated system for identification of *M.* tuberculosis complex and detection of rifampin
   resistance
- Decontamination, digestion, DNA extraction, amplification, and detection in a single cartridge
- Integrated positive control assures that a negative result is not due to NAA inhibitors in the specimen
- Results in ~2 hours
- Minimal hands on manipulation- technically simple
- Platform is random access


#### GeneXpert



- Target: rpoB gene
- Nested PCR and molecular beacon technology
- Same segment of the rpoB gene is used for detection of both M. tb complex and rifampin resistance
- PCR amplifies a small region relevant to rifampin resistance
- Uses 5 probes to assess for mutations

# Genetics of Rifampin Resistance in *M.*tuberculosis






# Specimen Requirements

- Quality specimen and adequate volume are critical
- Expectorated or induced sputum
- Specimen requirements may vary among laboratories
  - One specimen for both Xpert and smear/culture, 5-10 ml
    - Allows interpretation of Xpert in conjunction with AFB smear result
  - Two specimens
    - One for Xpert, 1-2 ml
    - Separate specimens for smear/culture





finddiagnostics.org


#### MTB/Rif Assay design




A C D

- 5'- GCACCAGCCAGCTGAGCCAATTCATGGACCAGAACCAGCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTG 3'
- 3'-CGTGGTCGGTCGACTCGGTTAAGTACCTGGTCTTGTTGGGCGACAGCCCCAACTGGGTGTTCGCGGCTGACAGCCGCGAC 5'

The MTB assay target is the 81 bp region (RRDR) of the rpoB gene.



Each probe is labeled with a different fluorophore, permitting simultaneous detection of the presence of wild type.



Ε

Example of Rif-Sensitive Profile – 5 probes are positive





- Limit of detection 131 CFU/ml
- M. tuberculosis viability minus 8 log
- 107 clinical specimens/suspicion of TB Vietnam
  - 100% 29/29 AFB smear + / Culture +
  - 84.6% 33/39AFB smear /solid Culture +
  - 71.7% 38/53AFB smear / solid & broth
     Culture

Helb et al. JCM 48:229-237 (2010)



# Reporting

- MTB Detected
- MTB Not Detected
- Invalid
  - Presence or absence of MTB could not be determined due to failure of the control
- Rifampin resistance detected
- Rifampin resistance not detected
- Rifampin resistance indeterminate



## Reporting

- May include interpretive comments
  - e.g A result of MTB not detected indicates infectious TB is not likely. Make the decision to discontinue airborne infection isolation in conjunction with clinical data.
- Who to report to?
  - Health care provider
  - Infection preventionist
  - TB Control Program
  - Local Public Health



## **Turn-around Time Expectations**

- Will vary with how laboratory is structured and staffed
  - Xpert system available onsite and raw sputum tested----2-4 hr
  - Xpert system offsite and raw sputum tested
    - Factor in transport time plus 2-4 hr
  - Xpert performed in the Mycobacteriology lab using processed sediment ----5 24 hr

FDA News Release

# New data shows test can help physicians remove patients with suspected TB from isolation earlier

Morbidity and Mortality Weekly Report

#### Revised Device Labeling for the Cepheid Xpert MTB/RIF Assay for Detecting Mycobacterium tuberculosis

Division of Microbiology Devices, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, Food and Drug Administration



 In February, 2015, the FDA approved a change in the package insert for the *GeneXpert*® to reflect expanded claims related to A.I.I.\*

#### Specifically:

... results using this assay on "either one or two sputum specimens" can be used as an alternative to examination of serial acid-fast stained sputum smears to aid in the decision to discontinue A.I.I. for patients with **suspected** pulmonary TB.

# Sensitivity of TB PCR, initial specimens on culture-positive TB patients

	Smear Positive	Smear Negative	Total
Respiratory	172/178	17/27	189/205
	(96.6%)	(62.9%)	(92.1%)
Non-	18/18	1/6	19/24
respiratory	(100%)	(16.6%)	(79.1%)
Total	190/196	18/33	208/229
	(96.9%)	(54.5%)	= 90.8%

9/2010 to 6/2015







Consensus statement on the use of

Cepheid Xpert MTB/RIF® assay in making
decisions to discontinue airborne infection
isolation in healthcare settings

#### Purpose:

To provide guidance on the use of the Xpert to discontinue airborne infection isolation (A.I.I.) for persons with suspected, infectious pulmonary tuberculosis (TB)

http://www.tbcontrollers.org/docs/resources/NTCA\_AP HL\_GeneXpert\_Consensus\_Statement\_Final.pdf





#### The Statement: What it IS

- Recommendations on how to interpret the GeneXpert ® MTB/RIF results
- A document
  - stressing the difference between diagnosis of TB and infectiousness of TB
  - providing easily followed instructions/protocols for sputum induction
  - containing a customizable flowchart for use in hospital policies and procedures manuals or as a decision-making tool
- A reminder of the importance of working with public health TB programs and the public health labs

#### The Statement: What it is NOT


- It is **NOT** a diagnostic algorithm
  - sputum smears and cultures are essential for identification of the organism, drug susceptibility testing, and genotyping
- NAA testing should not be used to monitor response to treatment or to release a newly confirmed TB patient from A.I.I.
- It is NOT an endorsement of Xpert or of any specific product
  - reflects new FDA approval of NAA technology that applies to the Cepheid Xpert MTB/RIF® system only and for this specific indication
- It is NOT a rationale for delaying the start of empiric treatment when TB is suspected








- 90 yr old man from the Philippines
- History of TB many years ago
- Hemoptysis with no other TB symptoms
- GeneXpert ® Positive
- Would you continue A.I.I.?
  - A. YES
  - B. NO






- 20 year old from Vietnam
- IGRA negative
- Calcifications in LUL consistent with granulomatous disease
- GeneXpert ® negative on one sputum
- Next step
  - A. Remove from isolation
  - B. Collect a 2<sup>nd</sup> sputum
  - C. Send him home






- 2<sup>nd</sup> Xpert NEGATIVE
- Discontinue isolation
  - YES
  - NO






- 17 year old male from China
- IGRA positive
- CXR with LUL calcification consistent with granuloma disease
- Nonproductive cough
- Xpert negative
- Next step
  - A. Remove from isolation
  - B. Collect a 2<sup>nd</sup> sputum
  - C. Send him home





- Second Xpert negative
- Discontinue Isolation?
  - Yes
  - No





• What if he had hemoptysis instead of dry cough?

• What if it was winter time and everyone in dorm had a cough?



## Summary

- The Consensus Statement addresses use of GeneXpert ® for release from A.I.I.
- It is not meant as a diagnostic algorithm
- Must be used in conjunction with patient's clinical data and risk factors

Suspect TB patients are reportable to public health





#### The A.I.I. Working Group:

Emily A. Anderson David Ashkin

Heidi Behm Robert L. Brawley

Maria Dalbey Andrea Forman

Phil Griffin Frances Jamieson

Kenneth C. Jost Jimmy Keller

Quratulain Kizilbash Maureen Murphy-Weiss

Diana Nilsen Susan Ray

Randall Reves Barbara Russell

Max Salfinger Caitlin Reed

#### Co-Chairs:

John Bernardo

**David Warshauer** 

#### **NTCA:**

Jennifer Kanouse Donna Wegener

#### **APHL:**

Anne Gaynor Paul Zell

#### CDC:

Neha Shah

Brian Baker Jimmy Keller